Methods for the treatment of HER2 amplified cancer
View Patent ↗Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib.
1. A method for treating a refractory HER2-amplified breast cancer in an individual in need thereof comprising administering to an individual in need thereof a composition comprising (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one
2. The method of claim 1 , wherein the refractory HER2-amplified breast cancer is metastatic.
3. The method of claim 1 , wherein the refractory HER2-amplified breast cancer is refractory to a treatment of trastuzumab, trastuzumab emtansine, pertuzumab, lapatinib, or MM-111.
4. The method of claim 1 , wherein the refractory HER2-amplified breast cancer has a HER2:CEP17 ratio of 2.2-4.0 or >4.0.
5. The method of claim 1 , further comprising co-administering an additional therapeutic agent.
6. The method of claim 5 , wherein the additional therapeutic agent is an anti-HER2 therapeutic agent, a pan-ErbB inhibitor, or an anti-VEGF therapeutic agent.
7. The method of claim 6 , wherein the anti-HER2 therapeutic agent is selected from the group consisting of: trastuzumab, trastuzumab emtansine, pertuzumab, lapatinib, and MM-111.
8. The method of claim 6 , wherein the pan-ErbB inhibitor is selected from the group consisting of: afatinib, neratinib, and dacomitinib.
9. The method of claim 6 , wherein the anti-VEGF therapeutic agent is selected from the group consisting of: bevacizumab, ranibizumab, lapatinib, sunitinib, sorafenib, axitinib, and pazopanib.
10. The method of claim 5 , wherein the additional therapeutic agent is selected from the group consisting of: temsirolimus; paclitaxel; varlitinib; vorinostat; doxorubicin; cyclophosphamide; cisplatin; docetaxel; dasatinib; trastuzumab and docetaxel; pertuzumab and docetaxel; doxorubicin, cyclophosphamide and paclitaxal; and doxorubicin, cyclophosphamide and fluorouracil.
11. A method for treating a refractory HER2 amplified cancer in an individual in need thereof comprising administering to an individual in need thereof a composition comprising (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one
12. The method of claim 11 , wherein the refractory HER2-amplified cancer is selected from the group consisting of: breast, colon, endometrial, cervical, urothelial, lung (including, non-small cell lung cancer), ovarian, gastric, gastroesophageal junction (GEJ), head and neck, biliary tract, prostate, and pancreatic cancer.
13. The method of claim 11 , wherein the refractory HER2-amplified cancer is metastatic.
14. The method of claim 11 , wherein the refractory HER2-amplified cancer has a HER2:CEP17 ratio of 2.2-4.0 or >4.0.
15. The method of claim 11 , wherein the refractory HER2-amplified cancer is refractory to a treatment of trastuzumab, trastuzumab emtansine, pertuzumab, lapatinib, or MM-111.
16. The method of claim 11 , further comprising co-administering an additional therapeutic agent.
17. The method of claim 16 , wherein the additional therapeutic agent is an anti-HER2 therapeutic agent, a pan-ErbB inhibitor, or an anti-VEGF therapeutic agent.
18. The method of claim 17 , wherein the anti-HER2 therapeutic agent is selected from the group consisting of: trastuzumab, trastuzumab emtansine, pertuzumab, lapatinib, and MM-111.
19. The method of claim 17 , wherein the pan-ErbB inhibitor is selected from the group consisting of: afatinib, neratinib, and dacomitinib.
20. The method of claim 17 , wherein the anti-VEGF therapeutic agent is selected from the group consisting of: bevacizumab, ranibizumab, lapatinib, sunitinib, sorafenib, axitinib, and pazopanib.
21. The method of claim 16 , wherein the additional therapeutic agent is selected from the group consisting of: temsirolimus; paclitaxel; varlitinib; vorinostat; doxorubicin; cyclophosphamide; cisplatin; docetaxel; dasatinib; trastuzumab and docetaxel; pertuzumab and docetaxel; doxorubicin, cyclophosphamide and paclitaxal; and doxorubicin, cyclophosphamide and fluorouracil.